Helsinn grants stendhal rights to Anamorelin, a first-in-class compound to treat cachexia-anorexia related to non-small cell lung cancer (NSCLC)
Lugano, Switzerland and Mexico City, Mexico (ots) - Stendhal strengthens its pipeline of in-licensed specialty drug products by signing a Distribution and License Agreement with Helsinn Group for an innovative phase III ghrelin receptor agonist. Swiss pharmaceutical Helsinn Group has granted Latin American specialty ...
mehr